Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Sorting nexin 10 sustains PDGF receptor signaling in glioblastoma stem cells via endosomal protein sorting
Ryan C. Gimple, … , Sameer Agnihotri, Jeremy N. Rich
Ryan C. Gimple, … , Sameer Agnihotri, Jeremy N. Rich
Published February 16, 2023
Citation Information: JCI Insight. 2023;8(6):e158077. https://doi.org/10.1172/jci.insight.158077.
View: Text | PDF
Research Article Oncology Stem cells

Sorting nexin 10 sustains PDGF receptor signaling in glioblastoma stem cells via endosomal protein sorting

  • Text
  • PDF
Abstract

Glioblastoma is the most malignant primary brain tumor, the prognosis of which remains dismal even with aggressive surgical, medical, and radiation therapies. Glioblastoma stem cells (GSCs) promote therapeutic resistance and cellular heterogeneity due to their self-renewal properties and capacity for plasticity. To understand the molecular processes essential for maintaining GSCs, we performed an integrative analysis comparing active enhancer landscapes, transcriptional profiles, and functional genomics profiles of GSCs and non-neoplastic neural stem cells (NSCs). We identified sorting nexin 10 (SNX10), an endosomal protein sorting factor, as selectively expressed in GSCs compared with NSCs and essential for GSC survival. Targeting SNX10 impaired GSC viability and proliferation, induced apoptosis, and reduced self-renewal capacity. Mechanistically, GSCs utilized endosomal protein sorting to promote platelet-derived growth factor receptor β (PDGFRβ) proliferative and stem cell signaling pathways through posttranscriptional regulation of the PDGFR tyrosine kinase. Targeting SNX10 expression extended survival of orthotopic xenograft–bearing mice, and high SNX10 expression correlated with poor glioblastoma patient prognosis, suggesting its potential clinical importance. Thus, our study reveals an essential connection between endosomal protein sorting and oncogenic receptor tyrosine kinase signaling and suggests that targeting endosomal sorting may represent a promising therapeutic approach for glioblastoma treatment.

Authors

Ryan C. Gimple, Guoxin Zhang, Shuai Wang, Tengfei Huang, Jina Lee, Suchet Taori, Deguan Lv, Deobrat Dixit, Matthew E. Halbert, Andrew R. Morton, Reilly L. Kidwell, Zhen Dong, Briana C. Prager, Leo J.Y. Kim, Zhixin Qiu, Linjie Zhao, Qi Xie, Qiulian Wu, Sameer Agnihotri, Jeremy N. Rich

×

Figure 12

SNX10 is a useful clinical target in glioblastoma, with prognostic importance in patient data sets, and is important for in vivo tumor formation capacity.

Options: View larger image (or click on image) Download as PowerPoint
SNX10 is a useful clinical target in glioblastoma, with prognostic impor...
(A) RNA-seq, whole exome, and clinical data (667 cases) were aggregated from TCGA glioblastoma (GBM) and low-grade glioma (LGG) data sets to visualize the expression of SNX10, PDGFRβ, and PDGFRβ signature genes across glioma. Codel, co-deletion of chromosomes 1p and 19q; PA-like, pilocytic astrocytoma–like; CIMP, glioma-CpG island methylator phenotype; LGm6-GBM, a subgroup enriched for histologic low-grade gliomas but also contains a subset of tumors with GBM-defining histologic criteria; KPS, Karnofsky Performance Status. (B and C) SNX10 mRNA levels based on (B) glioma grade or (C) glioma histology in patients from TCGA glioma data sets. ODG, oligodendroglioma; OAC, oligoastrocytoma; AC, astrocytoma; GBM, glioblastoma. (D) Analysis of patient survival in TCGA glioblastoma microarray (HG-U133A) data set for each gene defined in Figure 1G. The x axis indicates the difference in days between the high-expressing group and low-expressing group, with positive values indicating that high mRNA expression is associated with poor patient prognosis. Median expression value for each gene was used as a cutoff. The y axis indicates the significance of the prognostic effect. (E) SNX10 mRNA expression (log2-transformed transcripts per million) assessed by RNA-seq in 38 GSCs and 5 NSCs used in Figure 1A stratified by transcriptional subtype (27). (F and G) Kaplan-Meier curves showing survival of all glioma patients in the (F) TCGA or (G) CGGA data sets stratified by the median SNX10 mRNA expression. (H) Kaplan-Meier curve showing survival of all glioblastoma patients in Gravendeel data sets stratified by the median SNX10 mRNA expression. (I) Kaplan-Meier curve showing survival of glioblastoma patients with wild-type IDH in TCGA data sets, stratified by the median SNX10 mRNA expression. (J) Kaplan-Meier curve showing survival of all glioblastoma patients in TCGA data sets, stratified by the median SNX10 mRNA expression. (K and L) Kaplan-Meier curves showing the time until onset of neurological signs in intracranial xenografts derived from (K) GSC 3565 or (L) GSC CW468 transduced with 1 of 3 independent nonoverlapping shRNAs targeting SNX10 or a nontargeting shRNA (shCONT). P values were calculated by 1-way ANOVA with Tukey’s multiple-comparison test (B and C) or log-rank test (F–L). *P < 0.05; **P < 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts